C.R. Bard closes $200 M acquisition of SenoRx
C.R. Bard has closed on its acquisition of SenoRx, the medical device maker said Tuesday.
SenoRx makes devices used in detecting and treating breast cancer and in May, Bard announced it would buy the company for about $200 million.
SenoRx's products include the EnCor breast biopsy system, Gel Mark breast tissue markers, and Contura balloon catheter. Its revenue totaled $55.6 million in 2009.
The acquisition of SenoRx, based in Irvine, Calif., will reduce Bard's 2010 net income by 8 to 11 cents per share.
Bard said SenoRx Inc. is now part of its peripheral vascular unit.
Shares of C.R. Bard Inc. rose 98 cents to $77.46 Tuesday.